Equities

INIFY Laboratories AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

INIFY Laboratories AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)3.86
  • Today's Change-0.34 / -8.10%
  • Shares traded31.80k
  • 1 Year change-11.47%
  • Beta-0.4751
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

INIFY Laboratories AB is a Sweden-based medical research company that provides cancer diagnostics through laboratory services within pathology. The Company uses a fully digital, standardized and Artificial Intelligence (AI)- supported workflow to optimize quality and response times, initially within prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. INIFY Laboratories' laboratory in Solna, Sweden is intended to provide two types of analyses of prostate Biopsy Specimens to clients: Full pathology Report signed by an INIFY subspecialized pathologist and Whole Slide Images (WSI) generation and result of Pathology Decision Support Tool (PDST) analysis only. The Company origins from ContextVision.

  • Revenue in NOK (TTM)21.59m
  • Net income in NOK-65.84m
  • Incorporated2021
  • Employees34.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
iZafe Group AB6.34m-19.04m173.86m10.00--9.83--27.43-0.0614-0.06140.01940.04520.17573.448.15843,000.00-52.78-57.76-73.42-72.44-106.29-287.24-300.41-630.900.9122-17.450.0198--336.55-11.1036.26---24.50--
Bactiquant A/S12.66m-20.05m178.00m----11.37--14.06-0.4696-0.46960.29660.27230.46562.6915.14---73.73-55.41-85.85-64.53-31.80-10.94-158.37-121.813.26-9.700.1926---41.68-14.27-4.72------
Ortivus AB81.53m-26.57m180.70m34.00------2.22-0.5583-0.55831.71-0.50621.186.7716.222,372,281.00-38.46-4.62-147.30-8.6534.7941.27-32.59-3.550.4719-4.011.72---4.369.60-36.49--65.37--
BrainCool AB (publ)46.84m-39.57m190.84m20.00--1.00--4.07-0.1408-0.14080.16660.44790.28411.152.922,180,769.00-24.00-38.93-26.22-53.1029.8648.00-84.48-233.832.29-33.110.00--72.0556.5028.13--4.34--
Micropos Medical AB (publ)9.09m-21.71m191.33m9.00--8.99--21.05-0.1296-0.12960.05380.11910.3797-0.00315.091,057,905.00-90.68-74.98-115.26-98.65100.1587.53-238.83-670.954.49-70.700.00--133.4736.607.09------
Boule Diagnostics AB550.58m-86.65m208.53m186.00--1.15--0.3787-2.09-2.0913.334.341.034.614.042,268,420.00-16.14-9.09-28.43-13.2842.8843.62-15.74-11.160.775323.700.5491---2.252.28-1,287.41--7.84--
Subgen AI AB0.00-68.92m225.38m15.00---------544.10-544.100.00-25.110.00----0.00-188.83---403.12-------------4.46-----100.00--16.86------
SciBase Holding AB (publ)39.29m-97.08m235.75m34.00--3.93--6.00-0.2487-0.24870.09780.06740.66481.293.231,143,250.00-164.26-75.65-244.76-101.0166.0465.08-247.08-256.982.07-11.750.00--27.7926.21-9.97---20.49--
Prolight Diagnostics AB (publ)0.00-38.21m242.15m21.00--1.24-----4.03-4.030.0015.080.00----0.00-19.97---24.07--------------0.00------80.11---1.65--
Integrum AB104.17m-32.06m245.71m37.00--1.21--2.36-1.37-1.374.507.260.52530.8283.402,487,052.00-16.17-3.58-17.87-4.0875.6183.88-30.78-6.471.88--0.025---12.5027.78-864.22--103.14--
Clinical Laserthermia Systems AB22.84m-41.22m256.03m16.00--3.30--11.21-5.02-5.021.082.320.32084.584.841,329,313.00-57.98-116.28-63.60-248.44-63.75-556.78-180.75-872.822.55-5.790.0039--127.0467.4740.32------
Karolinska Development AB1.87m-145.78m261.72m8.00--0.0789--140.21-0.4096-0.40960.00523.280.0015--0.6263217,250.00-11.69-2.23-11.78-2.37-----7,810.36-1,161.99---1.490.0017---8.74-11.49-250.41------
ContextVision AB120.80m3.83m288.47m44.0075.972.9723.592.390.04910.04911.581.250.95751.744.153,020,009.003.0430.513.7145.0797.6298.493.1728.494.70--0.0847---1.156.51-24.6027.25-30.69--
INIFY Laboratories AB21.59m-65.84m310.02m34.00--2.20--14.36-1.15-1.150.37291.730.19282.963.12863,607.90-58.78---58.78--85.20---304.93------0.00--1,000.67--3.15------
Acarix AB7.43m-56.32m337.79m8.00--8.17--45.47-0.0472-0.04720.00620.03430.11960.16672.77864,750.00-90.68-74.33-102.27-86.4786.1582.37-757.98-1,298.777.93-805.720.00---0.624927.2814.97------
Mentice AB294.79m-46.51m410.80m121.00--3.04--1.39-1.68-1.6810.524.480.96631.603.942,095,328.00-15.25-6.64-31.60-11.9190.4084.80-15.78-8.530.845-30.100.116--6.1114.22-553.89--32.86--
Data as of Feb 06 2026. Currency figures normalised to INIFY Laboratories AB's reporting currency: Norwegian Krone NOK

Institutional shareholders

0.38%Per cent of shares held by top holders
HolderShares% Held
Aktia Bank Plc (Investment Management)as of 31 Oct 2025301.30k0.38%
Data from 30 Nov 2025 - 30 Nov 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.